Oligonucleotide Therapies Delivered to Kidney

Judo Bio is at the forefront of developing oligonucleotide medicines specifically designed for targeted delivery to the kidney, a previously challenging area for genetic therapies. The company has pioneered a novel approach that utilizes receptor-mediated uptake mechanisms to deliver small interfering RNA (siRNA) to specific kidney cell types. This is achieved through proprietary ligand-siRNA conjugates that bind to megalin receptors on proximal tubule epithelial cells (PTECs). By leveraging the natural recycling capabilities of these receptors, Judo Bio's technology enables effective gene silencing of disease-modifying target genes, thereby opening new avenues for treating systemic and renal diseases.

The STRIKE platform (Selectively Targeting RNA Into KidnEy) is central to Judo Bio's strategy, allowing for the selective delivery of siRNA therapeutics to the kidney. The megalin receptor, which is highly expressed on PTECs, serves as a critical entry point for these ligand-siRNA conjugates. Once internalized, the siRNA degrades the mRNA of specific solute carrier proteins, which are implicated in various systemic diseases. This targeted approach not only enhances the therapeutic potential of oligonucleotide medicines but also expands the possibilities for treating a range of conditions, including metabolic disorders and kidney diseases, by utilizing the unique physiology of the renal system.

United States

Judo Bio is a biotechnology company focused on developing precision therapeutics against genetic disorders. The company has raised a total funding of $20M over 1 round and is known for its innovative approach to drug development.

Judo Bio

Company Details